Guillain-Barré Syndrome Complicating Mobilization Therapy in a Case of B-cell Chronic Lymphocytic Leukemia

We report a case of Guillain-Barré Syndrome (GBS) which appeared after mobilization therapy in a patient with B-cell chronic lymphocytic leukemia (B-CLL). After obtaining a partial remission with four cycles of fludarabine at standard dose, the patient underwent to high-dose Cytoxan in order to mobilize CD34+ hematopoietic progenitor cells. During neutropenia the patient experienced fever of unknown origin (FUO) and subsequently developed GBS with normalization of his neurologic condition after 2 months. It is possible that a viral-induced activation of an antigen-specific T and B-cell clone caused a local inflammation and toxicity of Schwann cells with demyelination and axonal damage with a self-limited course.

[1]  J. Raphaël,et al.  [Guillain-Barré syndrome]. , 2005, La Revue du praticien.

[2]  R. Hughes,et al.  Guillain-Barré syndrome , 2004, The Lancet.

[3]  H. Heslop,et al.  Guillain–Barré syndrome after allogeneic hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.

[4]  P. Wen,et al.  Guillain-Barré syndrome following allogeneic bone marrow transplantation , 1997, Neurology.

[5]  W. Peters,et al.  Guillain‐Barre Syndrome Following Autologous Bone Marrow Transplantation , 1995, American journal of clinical oncology.

[6]  J. Mehta,et al.  Guillain-Barré syndrome after bone marrow transplantation. , 1994, Bone marrow transplantation.

[7]  O. Abramsky,et al.  Acute inflammatory demyelinating polyneuropathy following bone marrow transplantation. , 1991, Bone marrow transplantation.

[8]  R. Warrell,et al.  Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.